European journal of medical research · 2025
Exploration of novel therapeutic targets for keloids based on clinical and molecular data: the role of the IL-4/IL-13 signaling pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xueli, Lan Jianping, Liu Ruoyun, Lin Tingting, Li Zheqi, Cheng Bo
Аннотация
BACKGROUND AND OBJECTIVES: Keloids are problematic fibrotic lesions with excessive collagen and chronic inflammation; their underlying causes are not fully understood. Type 2 helper T (Th2) cytokines IL-4 and IL-13 are implicated in various fibrotic disorders, including but not limited to pulmonary fibrosis and systemic sclerosis. This study aimed to investigate the IL-4/IL-13 signaling pathway's contribution to keloid pathophysiology and evaluate its potential as a novel therapeutic target.
METHODS: We retrospectively analyzed keloid patients, collecting demographic data and grading scar severity with the Vancouver Scar Scale (VSS). Keloid tissue specimens underwent immunofluorescence, Western blotting, and real-time PCR to quantify IL-4, IL-13, Type I Collagen alpha 1 (Collagen I A1), and phosphorylated STAT6 (p-STAT6) expression.
RESULTS: Patients had an average total VSS score of 11.0 ± 2.9, indicating active fibrotic inflammation. Molecular assays showed significant upregulation of IL-4 and IL-13, alongside increased p-STAT6 and Collagen I A1 in keloid tissues. Notably, IL-4, IL-13, and p-STAT6 expression positively correlated with VSS thickness and pliability scores.
CONCLUSIONS: Our findings demonstrate that the IL-4/IL-13 signaling axis is markedly activated in keloid tissues, promoting collagen synthesis via STAT6 phosphorylation. Therefore, targeting the IL-4/IL-13/STAT6 pathway may represent a promising therapeutic strategy for managing keloids.
METHODS: We retrospectively analyzed keloid patients, collecting demographic data and grading scar severity with the Vancouver Scar Scale (VSS). Keloid tissue specimens underwent immunofluorescence, Western blotting, and real-time PCR to quantify IL-4, IL-13, Type I Collagen alpha 1 (Collagen I A1), and phosphorylated STAT6 (p-STAT6) expression.
RESULTS: Patients had an average total VSS score of 11.0 ± 2.9, indicating active fibrotic inflammation. Molecular assays showed significant upregulation of IL-4 and IL-13, alongside increased p-STAT6 and Collagen I A1 in keloid tissues. Notably, IL-4, IL-13, and p-STAT6 expression positively correlated with VSS thickness and pliability scores.
CONCLUSIONS: Our findings demonstrate that the IL-4/IL-13 signaling axis is markedly activated in keloid tissues, promoting collagen synthesis via STAT6 phosphorylation. Therefore, targeting the IL-4/IL-13/STAT6 pathway may represent a promising therapeutic strategy for managing keloids.